CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours | Nature
T-cell activation by anti-CTLA-4 antibodies. Notes: (A) Tumor antigens... | Download Scientific Diagram
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling | Nature Cancer
Definition of CTLA-4 - NCI Dictionary of Cancer Terms - NCI
Molecules | Free Full-Text | Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology | HTML
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners | SpringerLink
800 Dual targeting of CTLA-4 and CD47 on Treg cells rejuvenates immunity against solid tumors | Journal for ImmunoTherapy of Cancer
Localized low-dose anti-CTLa4 antibody therapy is efficacious. (A-C)... | Download Scientific Diagram
Rotavirus vaccine and anti-CTLA-4: a dynamic duo
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy | Cell Research
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade - ScienceDirect
Anti-mCTLA4 Monoclonal Antibody | Murine Recombinant 9D9
800 Dual targeting of CTLA-4 and CD47 on Treg cells rejuvenates immunity against solid tumors | Journal for ImmunoTherapy of Cancer
Reduce, Reuse, Recycle to improve anti-CTLA-4 therapy
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice | Cell Research
Frontiers | Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody | PNAS
Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response - ScienceDirect
Immunothérapie dans les cancers digestifs – FMC-HGE
Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
John Libbey Eurotext - Journal de Pharmacie Clinique - PK/PD relationships of therapeutic monoclonal antibodies used in oncology
Response to anti-CTLA-4 immunotherapy Day 16 post-YUMMER1.7... | Download Scientific Diagram
Mechanism of action of anti-PD-1, anti-PD-L1, and anti-CTLA4.... | Download Scientific Diagram
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy | Cell Research
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners | SpringerLink
Schematic representation of CTLA-4 and anti-CTLA-4 mechanisms of action... | Download Scientific Diagram
